| Document |
Document Title |
|
WO/2017/083967A1 |
The present invention provides purified compounds extracted from seaweeds having the formula (I): wherein R1 and R2 is each independently H or a fatty acid and their use for inhibiting the growth of cancer cells.
|
|
WO/2017/084987A1 |
The invention comprises Gal NAc phosphoramidite derivatives of the formula (I), wherein R1 is a hydroxy protecting group, n is an integer from 0 to 10 and m is an integer from 0 to 20 and its corresponding enantiomers and/ or optical iso...
|
|
WO/2017/075994A1 |
Provided are a separation and purification method for epirubicin or hydrochloride thereof. The method comprises: 1) taking epirubicin or a hydrochloride crude product thereof, and sampling macroporous absorption resin; and 2) carrying ou...
|
|
WO/2017/079582A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
|
WO/2017/078609A1 |
The present invention relates to a metal-organic framework with encapsulated target-molecule, a process for the preparation of a metal-organic framework with encapsulated target-molecule, as well as the metal-organic framework with encap...
|
|
WO/2017/078097A1 |
Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.
|
|
WO/2017/078098A1 |
Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.
|
|
WO/2017/078096A1 |
Provided is a method for efficiently producing a compound represented by formula II, namely (2S)-2-hydroxyarbekacin or a salt thereof from (2S)-2-hydroxydibekacin represented by formula I or a salt thereof, which is characterized by usin...
|
|
WO/2017/071152A1 |
Provided are a phosphoryl mannose pentasaccharide as shown in formula (I) and derivatives of the phosphoryl mannose pentasaccharide as shown in formulas (II)-(XI), and a preparation method thereof. In the preparation method of this inven...
|
|
WO/2017/063617A1 |
The present invention relates to a preparation method of the intermediates of structures la (for the synthesis of canagliflozin) and 1b (for the synthesis of dapagliflozin), where in structure la X is methyl and Ar represents 2-(5-(4-flu...
|
|
WO/2017/062800A1 |
Disclosed are compounds for the selective labeling of cell-surface sugars in cancer cells. The compounds are activatable by triggers specific to cancer cells, and, when metabolized, label a cancer cell surface sugar with an azide chemica...
|
|
WO/2017/058474A1 |
Prepare a branched alcohol-based sugar surfactant by: (a) providing an ether alcohol and a fully acetylated sugar where the ether alcohol has the structure of Structure (I); (b) coupling the ether alcohol with the acetylated sugar in the...
|
|
WO/2017/059318A2 |
The present disclosure relates to scaphopetalone analogs, methods of making the analogs, and their medicinal uses.
|
|
WO/2017/051875A1 |
Provided is a compound represented by formula (I) or a salt thereof (in formula (I): R1 and R2 each represent hydrogen, a C1-5 straight-chain or branched alkyl group, a C1-5 straight-chain or branched alkoxy group, or a C1-5 straight-cha...
|
|
WO/2017/049386A1 |
This invention discloses the use of aminoglycoside antibiotics such as gentamicin Bl to suppress premature termination codons during translation and promote the full length read-through of transcripts such as p53 that incorporate nonsens...
|
|
WO/2017/046172A1 |
The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the g...
|
|
WO/2017/046535A1 |
The subject matter of the present invention is a compound characterized in that it has the general formula (I): in which P1, X, n, A, L and L1 are as defined in Claim 1. The present invention also relates to a process for preparing said ...
|
|
WO/2017/043703A1 |
The present invention relates to a mannitol-based amphipathic compound, a method for preparing the same, a method of extraction, solubilization, stabilization or crystallization of a membrane protein using the same, and a method for anal...
|
|
WO/2017/037719A1 |
Novel aminoglycosides, represented by Formulae la and lb, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the s...
|
|
WO/2017/037718A1 |
Novel pseudo-trisaccharide aminoglycosides, represented by Formula I, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions cont...
|
|
WO/2017/039107A1 |
The present invention relates to a xylene-based amphipathic compound, a method for preparing same, and a method for extracting, solubilizing, stabilizing, or crystallizing membrane proteins by using said compound. By using the xylene-bas...
|
|
WO/2017/037717A1 |
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are p...
|
|
WO/2017/027968A1 |
Adjuvants which rescue antibiotics against multidrug-resistant (MDR) organisms are a promising combination strategy to overcome bacterial resistance. While the combination of β-lactam β-lactamase inhibitor antibiotic has been successfu...
|
|
WO/2017/031189A1 |
The invention provides compositions and methods for the production of TDP-deoxysugars.
|
|
WO/2017/021385A1 |
The invention comprises a new process for the preparation of GalNAc derivatives of the formula I wherein n is an integer between 0 and 10 and its salts, corresponding enantiomers and/ or optical isomers thereof. The GalNAc acid derivativ...
|
|
WO/2017/017509A1 |
The present invention relates to novel oligomers of Neisseria meningitidis serogroup Y capsular polysaccharide repeating unit (Men-Y oligomers) and process for synthesizing novel Men- Y oligomers. In particular, the present invention rel...
|
|
WO/2017/019599A1 |
A process for the extraction and concentration of saponins from agricultural feedstocks. An agricultural feedstock can undergo a first preparation step intended to increase surface area of the feedstock for increased efficiency in extrac...
|
|
WO/2017/018528A1 |
Disclosed are: a compound represented by general formula (I), or a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt; a pharmaceutical composition containing the compou...
|
|
WO/2017/012289A1 |
Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said com...
|
|
WO/2017/012572A1 |
Provided are crystalline form A of rebaudioside D, and a preparation method and application therefor. In X-ray powder diffraction analysis measured using Cu-Kα rays and with 2θ being expressed in degrees, crystalline form A of rebaudio...
|
|
WO/2017/007346A1 |
The present invention relates to novel derivatives of polyphenol glycoside or polyalcohols of formula (1), wherein R1, R2, R3 is selected from the group consisting of H, OH, C(O)R4, C(0) OR4, 0 (Gly H3)n, wherein n = 0 1, 2, 3, and R4 is...
|
|
WO/2016/202310A1 |
A sulphonated pentasaccharide compound having anti-Xa factor activity, and a preparation method and use for said compound. The compound is a derivative of a pentasaccharide compound having an anticoagulation effect, and has significant a...
|
|
WO/2016/198170A1 |
The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and p...
|
|
WO/2016/196927A1 |
Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5- amino-6-(((lR,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5
-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yl)
oxy)-2-hydroxycyclohexyl)oxy)-2- (h...
|
|
WO/2016/189179A1 |
The invention relates to a compound of general formula (I), and to the use thereof in medicine, or for the production of a medicine for the treatment of different diseases, preferably a cancer such as melanoma, lung carcinoma or breast c...
|
|
WO/2016/188381A1 |
The present invention relates to the technical field of medical compounds, and relates to an oxidized β-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. In the present invention, by using abundant cellulose ...
|
|
WO/2016/190383A1 |
A compound represented by structural formula (A) or (B); a method for producing the compound; a microorganism having an ability of producing the compound represented by the formula (A) or (B); and a compound-containing composition and an...
|
|
WO/2016/181013A1 |
The invention relates to the use of oligosaccharides as stimulators of plant growth in already germinated plants and to a method for obtaining said oligosaccharides. The invention particularly relates to the use of oligosaccharides compo...
|
|
WO/2016/180818A1 |
The present invention relates to glycosylating polyphenols via biocatalysis. More specifically the present invention discloses particular mutants of the thermostable sucrose phosphorylase derived from the microorganism Thermoanaerobacter...
|
|
WO/2016/180729A1 |
Apparatus and methods for reducing biofouling in drink such as beer dispensing equipment are described.
|
|
WO/2016/173425A1 |
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compou...
|
|
WO/2016/169288A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a new amorphous piceatannol 3'-O-glucoside, preparation method thereof, and pharmaceutical composition containing the same. The amorphous piceatannol 3...
|
|
WO/2016/172615A1 |
The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and et...
|
|
WO/2016/164921A1 |
In various embodiments, the invention provides a radiotracer comprising a positron emitting atom bound to a deoxy sugar moiety. The radiotracer is reversible bound to a caging moiety that prevents or retards tissue uptake of the radiotra...
|
|
WO/2016/161951A1 |
A phillygenin glucuronic acid derivative represented by general formula (I). In general formula (I), R1=H, R2=CnH2n+1, and R3=CnH2n+1; or R1=CnH2n+1, R2=CnH2n+1, and R3=H; or R1-R2=-CH2-, and R3=CnH2n+1; n=1 to 30. The present invention ...
|
|
WO/2016/164394A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed, For example, E-selectin antagonist therape...
|
|
WO/2016/161377A1 |
This disclosure relates to the incorporation of amphiphilic guanidinylated aminoglycosides (e.g., neomycin) into liposomal assemblies, which contain entrapped therapeutics. The lysosome is responsible for enzymatically breaking down and ...
|
|
WO/2016/156338A1 |
The present invention relates to synthetic saccharides of general fornnula (I): V*−[Ux+2−Ux+ 1−Ux]n−V−O−L−NH2 that are related to carbapenem-resistant Kliebsella pneumoniae capsular polysaccharide and conjugates thereof. Sa...
|
|
WO/2016/159537A1 |
The present invention relates to a phytospingosine derivative generated by a condensation reaction of phytospingosine and maltose or lactose, which is an aldose-based disaccharide, and to a composition containing the same. The phytosping...
|
|
WO/2016/159092A1 |
In the present invention, an organic acid salt of 4'-epidaunorubicin or a hydrate or a solvate thereof is used as a novel production intermediate, whereby it is possible to efficiently remove 13-dihydroepidaunorubicin and 4'-epifeudomyci...
|
